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ABSTRACT
GABAergic-Related Pathology in the Anterior Cingulate Cortex of Postmortem Human Brain
Tissue in Autism Spectrum Disorder
by
Gethein Andrew
The anterior cingulate cortex (ACC) is part of the cognitive and emotional brain circuitry that
mediates social interaction. Imbalances between inhibitory, GABAergic neurons, and excitatory,
glutamatergic neurons, in this region are essential to brain circuity during social responses and
are thought to be involved with behaviors associated with autism spectrum disorder (ASD).
Enriched cell populations of glutamatergic neurons, obtained through laser capture
microdissection, were used for gene expression studies of GABAergic receptors (GABRA1,
GABRA4, and GABBR1). Additionally, proteins that impact GABAergic synapses (Spinophilin,
CPLX1, mTOR, IGF1R, PSD95, PARP1) were investigated using Western Blotting with punchdissected homogenate brain tissue from ACC and frontal cortical brain regions. No significant
differences in gene expression nor protein were identified between ASD and control brain
donors. Evidence of GABAergic synaptic pathology was not found; however, future studies of
alternative GABAergic markers and increased study numbers are needed to confirm these
findings in ASD human tissue.
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In hopes that my research makes a difference, I would like to dedicate this to
the research scientists who come after me. May my data collection help them advance their own
projects and bring a better understanding to the world of Autism Spectrum Disorder.
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CHAPTER 1. INTRODUCTION
Autism Spectrum Disorder
Autism Spectrum Disorder (ASD) is a term coined in 1943 to name a
neurodevelopmental disorder that affects human beings across the globe regardless of racial,
ethnic, and socio-economic boarders. Autism is considered a spectrum disorder meaning that
individuals with the disorder can have a very heterogenous symptom presentation i.e. complete
lack of verbal communication or mildly impaired verbal skills. Changes made to the fifth edition
of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) indicate the previous four
distinct disorders including classic autism, Asperger’s disorder, childhood disintegrative
disorder, or pervasive developmental disorder are now blanketed under the term “autism
spectrum disorder”. 1 The disorder now affects 1 in 54 children in the United States with rates as
high as 1 in 34 in males.2 The economic burden of ASD in the U.S. alone is approaching ten
billion annually. This cost is related to the nature of the disorder including a diagnosis before the
age of three and needing lifelong services. Comorbidities such as intellectual disabilities that
need special education classes and safe spaces to socialize are necessary and costly for families. 3
Twin Studies
Currently, no effective pharmacological treatments exist to prevent, slow, or cure ASD
increasing the urgency for understanding the pathobiology and progression of this disorder. Illdefined pathophysiology and the lack of molecular markers of ASD translates to a purely
behavioral diagnosis. The discovery of molecular markers by genetic studies or protein markers
for ASD could lead to development of diagnostic methods and novel treatments. Genetics have
been implicated in the development of ASD for over a decade which has led to several genetic
and genomic approaches to provide evidence of the disruption of biological pathways. Some of
10

the most conclusive genetic studies of ASD use monozygotic (MZ) and dizygotic (DZ) twins
where MZ twins share 100% of their genetic material while DZ share significantly less, but both
MZ and DZ share the same in-utero environment. Comorbid rates of approximately 36 to 95%
was found in MZ twin pairs providing support for a genetic etiology of ASD.4,5
Genetic Findings Associated with ASD
Genetics are likely involved in the etiology of ASD. Proband studies in ASD patients
and families using blood and urine indicate that first-degree relatives have an increased risk for
autism when certain variants are present such as Fragile X which is caused by de novo DNA
mutations. 5,6 Banding pattern analyses revealed that 12-20% of the ASD probands exhibited a
lesser variant, a gene variant that is more rare, which suggests autism etiology likely involves
several genes that lead to the observed phenotype.5,7 A recent large-scale exome sequencing
analysis using ASD patients revealed changes in genes specifically associated with neuronal
communication.8 Researchers in that study used a cohort of 35,500 samples (12,000 ASD
patients) to identify 102 ASD risk genes with 26 demonstrating significant correlations with
autosomal dominant neurodevelopmental disorders and another 30 having no previous
relationship with ASD.8 These genetic studies suggest that unique cell types including neurons
are different in ASD. Single nucleotide polymorphisms (SNP) are postulated to be the source of
most genetic variation in disorders with behavioral phenotypes, but recently it has been found
that rare copy number variants (CNV) can also have an influence on phenotype in both
behavioral and cognitive disorders. CNV’s are known to cause diseases with ASD-like behaviors
such as Fragile X syndrome.9 Gamma-Aminobutyric Acid A receptor Beta3 subunit (GABRβ3)
is a protein subunit for ligand gated ion channel Gamma aminobutyric acid (GABAA) that is
critical for ion channel function, the inhibition of neurotransmission. Comparative genomic
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hybridization tools used to analyze the GABRβ3 gene in the novel maternal 15q duplication
model found that CNVs were present that led to methylation differences between parental
variants that inhibited gene regulators from binding to the DNA and resulted in gene expression
reductions of GABRβ3.10 Current genetic studies in ASD have identified unique SNP’s in genes
associated with neurotransmission.11,12 Genotype studies of GABRβ3 using buccal swabs from
530 participants (N=530 with 412 control and 118 ASD patients) found that three different SNPs
were found on chromosome 15 in ASD participants.11 Genetic alterations have been denoted in
glutamatergic receptors as well. Glutamatergic receptors, N-Methyl-D-aspartic acid or NMethyl-D-aspartate, (NMDA), and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid,
(AMPA), are responsible for the excitation and depolarization of the post-synaptic neuron
transmitting the action potential. Mutations in these cell receptors can cause inactivation that can
affect neurotransmission. Genetic analysis of blood from 151 ASD patients showed that four of
the twelve unique SNPs in the NMDA glutamate receptor 2B (GRIN2B) were associated
between haplotypes, a group of genes inherited from one parent.12 Additionally, knock out
studies of CPLX1 (Complexin 1) in mice displayed social behavior deficits that were thought to
be related to calcium-mediated receptor exocytosis as the protein regulates fusion of synaptic
soluble NSF attachment protein receptor (SNARE) vesicles to regulate glutamate release.13,14
CPLX1 has also been found to be affected by CNVs that are specific to SNARE vesicle
exocytosis in neurons, which could easily affect neural function.15 The previous studies focus on
variations in single genes i.e. GABRβ3, GRIN2B, and CPLX1 in ASD; however, fragile X,
tuberous sclerosis complex, and chromosome 15 deletions are disorders with unique, single gene
etiologies that exhibit ASD behaviors in some but not all of patient base.16 It is unlikely that a
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single gene mutation results in ASD behaviors, but rather a poly-genetic profile is associated
with ASD behaviors that contributes to disrupted neuronal function.
Intraneuronal Communication between Pyramidal and Interneurons in the ACC
ASD is a neurodevelopmental disorder with a likely pathophysiological underpinning
associated with neuron-to-neuron communication between brain regions that result in social
ineptitudes and common overstimulation. The anterior cingulate cortex (ACC) is a brain region
that is involved in emotional and attentive responses to stimulation in mammalian species as
shown through functional magnetic resonance imaging (fMRI) studies.17 Activation of the ACC
occurs through the excitatory actions of glutamate neurons in the brain via synaptic transmission
between two cells termed the presynaptic and postsynaptic cells. The two cells communicate via
chemical signals through specific regions of the postsynaptic neuron known as the dendrite.
Inhibition of glutamatergic action potentials is attributed to the release of GABA
neurotransmitter from GABAergic neurons, or interneurons. Binding of GABA to GABAergic
receptors on postsynaptic glutamatergic neurons opens ion channels to hyperpolarize the cell.
Neurabin II, or Spinophilin, is a protein that is known to regulate dendritic spine density and
synaptic activity, which specifically relates to GABA neurotransmitter release due to the
necessity of a mature and functional dendritic spine. Researchers found that Spinophilin knockout mice had increased dendritic spine number, and a 34.6% increase in spine density.18 In the
same study, cultured neurons from the knock-out (KO) mice demonstrated a larger number of
filopodia, plasma membrane protrusions the cell uses to probe its environment, even though the
KO mice had the same amount of nerve terminals as the wild-type (WT) mouse strain.18 Postsynaptic density protein 95 (PSD-95) is another anchoring protein that is involved specifically in
the localization of glutamate receptors AMPA and NMDA.19 De novo CNVs studies comparing
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ASD, schizophrenia, and attention deficit hyperactivity disorder (ADHD) patient’s DNA to their
parents revealed that no mutations were found in glutamate receptors but instead mutations were
found in glutamate receptor scaffold-associated signaling proteins such as Membrane Associated
Guanylate Kinase (MAGUK) scaffold proteins which function in cellular signal transduction and
are strictly regulated by phosphorylation.20,21 Scaffold-associated signaling proteins such as
spinophilin and PSD-95 bring synaptic elements close enough to participate in the signaling
cascade. Mutations in signaling proteins could cause disruptions in cell survivability, gene
transcription, mRNA translation, protein folding, and even dendritic development that could play
a role in ASD progression and etiology.20 Evidence for these disruptions in ASD has not been
completely characterized; but, four possible signaling scenarios could exist between excitatory,
glutamatergic pyramidal neurons and inhibitory, GABAergic interneurons in the ACC of ASD
including (1) pyramidal to pyramidal disruptions, (2) pyramidal to interneuron disruptions, (3)
interneuron to pyramidal disruptions, or (4) interneuron to interneuron disruptions.22 Alterations
to one or both cell types may contribute to an excitatory and inhibitory (E/I) imbalance in ASD.
ASD Co-Occurrence with Epilepsy
A link between ASD and GABAergic (inhibitory) dysfunction has been shown through
investigations of co-morbid diseases with ASD. Epidemiology studies have found that ASD has
a 33% comorbidity with epilepsy affecting one third of the ASD community.16 In epilepsy, it has
been shown that GABAergic inhibition counterbalances glutamatergic excitation to prevent
excessive neuronal firing. Drugs that enhance GABAergic conductance i.e., phenobarbital were
used in rats to show desynchronize convulsive actions to moderate physiological levels of
chloride (Cl-) ions. Chloride ions are the main negative charge carrier involved in signal
conductance and are responsible for hyperpolarizing the cell to inhibit action potentials when
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GABAergic ion channels are activated.23 However, phenobarbital, a drug known to increase the
inhibitory actions of GABA, had no effect on convulsions when Cl- levels were increased until
bumetanide was used to lower Cl- levels back to a moderate physiological level. This
phenomenon occurs because when an increased amount of Cl- is in the cell it results in a
decrease in the inhibitory power of GABA neurotransmitter which results in seizures, which also
explains why bumetanide is able to restore the inhibitory effects of phenobarbital, by lowering
Cl- levels.24 Researchers studying the co-occurrence of epilepsy and ASD found the chance that
epilepsy occurred in the ASD patient increased as their IQ decreased. This research, done with
N=2644 ASD patients, compared co-occurrence rates based on IQ groups (<40, 40-50, 50-70,
>70) and found the highest rate to be 46% in the <40 group. These findings suggests that the
pathology of ASD intertwines with epilepsy pathology and could be associated with the E/I
neuronal imbalance.16
Neurotransmitter Serum Levels Support E/I Imbalance
It is hypothesized that enhanced glutamatergic signaling might be present in ASD with
support from correlations between plasma levels of glutamate and the severity of autism.25–27
Modulation of glutamate transporters can occur through either slow or rapid regulation by
negative feedback systems and amino acid phosphorylation that facilitates glutamate
excitotoxicity in ASD.28 A study of 931 participants using blood plasma of ASD patients found
significant associations between glutamate signaling genes such as GRIN2B and hyperactivity/
impulsivity symptom severity in ASD.26 A similar study using twenty ASD patients and typically
developing (TD) controls showed that ASD patients had a 57% increase in GABA, a 36%
increase in glutamate neurotransmitters, and a 13% increase in the glutamate/GABA (E/I) ratio
measured via enzyme-linked immunosorbent assay (ELISA).25 Additionally, plasma studies
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using forty ASD and thirty-eight TD age-matched controls indicated that the ASD group
demonstrated a significant increase in GABA levels and glutamate/glutamine ratios when ELISA
was performed thus implicating a possible impairment in the GABA/glutamate balance that
results in increased glutamate neurotransmission in ASD.27 Glutamate and GABA
neurotransmitter metabolism is hypothesized to play a role in cortical excitability. GABA
neurotransmitter, formed from glutamate by glutamic acid decarboxylase 65 (GAD65), is
“pooled” in nerve terminals at 50-100 mM concentrations; whereas GABA neurotransmitter
synthesized by glutamic acid decarboxylase 67 (GAD67) is distributed into the neuronal cytosol.
Gad67 KO mice die shortly after birth and have 7% of the brain GABA concentration of WT, but
the mice heterozygous for GAD67 have 65% of the brain GABA concentration.29 Functional
GAD proteins are also inhibited by GABA concentration in a negative feedback loop. Studies
have suggested that increased GABA levels decrease the activity of GAD and therefore decrease
GABA synthesis by 70% in 24 hours.29 It is also suggested that glutamatergic neurons
expressing GABA transporters are able to uptake released GABA neurotransmitter and recycle
the molecule to form glutamate.29 The plasma studies of glutamate compared in parallel with the
metabolism of GABA could suggest that there are higher levels of GABA in the blood plasma
because of the negative feedback loop that disables GAD activity and because glutamatergic
neurons are capable of recycling released GABA into Glutamate.29
Brain imaging of live ASD patients is a technique that can be used in living ASD patients
to determine changes in unique brain regions that may occur due to possible alterations in
neurotransmission. Magnetic resonance imaging (MRI) studies have shown that individuals with
ASD have a 5-10% enlargement in total brain volume in young children compared to TD peers
as well as a 6-12% increase in gray matter volume in adolescence.30 This enlargement of grey
16

matter in ASD could be attributed to abnormal cell proliferation that occurs during the first and
second trimesters of pregnancy. Disruption of cellular proliferation can affect differentiation,
maturation, and concentration. MRI studies were used to determine that ASD neuronal
progenitor cells displayed excessive proliferation when compared to TD neuronal progenitor
cells in toddlers. To gain neural progenitor cells for the study, researchers took induced
pluripotent stem cells from fibroblasts in living ASD toddlers and differentiated them into
neurons which allowed for the study of neuronal maturation and growth regulation.31 Imaging of
brain areas associated with social behaviors are particularly important in ASD studies. The social
brain is a term that encompasses many specialized but shared cognitive, emotional, and social
brain systems that mediate social interaction.32 For example, the amygdala is important for
recognizing expressions such as fear while the anterior cingulate cortex (ACC) is involved in
complex cognitive functions such as empathy and impulse control.33 fMRI of 1,112 participants
(539 ASD, 573 controls) showed that ASD demonstrates reduced functional connectivity
between the caudal ACC and sensorimotor sub-regions that are thought to contribute to the
severity of ASD.17 Also, fMRI studies using 21 ASD patients and TD controls implicated
differences of the mirror neuron system in the fusiform, temporal, and parietal brain regions
thought to contribute to social deficits.34 Not only have genetic studies supported an imbalance in
excitatory and inhibitory neurotransmitters25, but proton magnetic resonance spectroscopy
([1H]MRS) in the striatum and medial prefrontal cortex of ASD patients demonstrated
significant reductions of glutamate in the striatum that was correlated with worsening social
function.35 Overall, brain imaging studies of ASD have one common theme: differences in total
brain volume when compared to TD children does correlate with social communication deficits.
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BDNF/NTRK2 Signaling Cascades
ASD behaviors could result from synaptic malformations or dysfunction of GABAergic
and glutamatergic signaling in the ACC brain region. A current need in ASD research involves
studies of dendritic spine development and plasticity in ASD. Dendritic spines as mentioned
previously are small protrusions extending from dendrites to serve as the postsynaptic site of
excitatory glutamatergic and inhibitory GABAergic synapses in the brain. Brain-Derived
Neurotrophic Factor (BDNF) is a growth factor that participates in axonal and dendritic
differentiation during embryonic development, neurogenesis, and synaptic maintenance and
plasticity.36,37 BDNF is synthesized in the endoplasmic reticulum as Pro-BDNF, a precursor to
the mature form that undergoes cleavage of the terminal domain to become mature-BDNF.36
BDNF binds to the neurotrophic receptor tyrosine kinase 2 (NTRK2-gene and trkB-protein) to
induce three distinct signaling pathways: Ras/ mitogen-activated protein (MAP) kinase,
Phospholipase C, and Phosphoinositide-3’ (PI3) kinase that are involved in neurite outgrowth,
neurogenesis, and synaptic plasticity.38 The BDNF-NTRK2 pathway can affect the expression of
the GABAergic receptor families, GABAA and GABAB. For example, GABAAα and GABRAβ
receptors (multiple subunits) form ligand-gated ion channels, ionotropic channels, while GABAB
receptors (GABBR1 and GABBR2) heterodimerize to form G-protein coupled receptor
channels.39 The GABBR1 subunit contains the GABA binding site but cannot activate the Gprotein without dimerization of the GABBR2 subunit that contains a heptahelical domain that
allows for a functioning G-protein coupled receptor.40 The GABAB G-protein coupled receptor is
involved in pumping K+ out of the cell, bringing Ca2+ into the cell and the inhibition of adenylyl
cyclase that result in lowering cyclic adenosine monophosphate (cAMP) levels. These functions
enhance GABA receptor signaling which increases the inhibitory actions of GABA to regulate
glutamatergic signals.41 For example, GABAα1 are membranous pore forming proteins that
18

allow chloride to flow into the cell upon GABAergic binding. GABRA1 gene expression and
GABAAα translation can be activated by the binding of BDNF protein to the trkb receptor.
Binding of the GABA neurotransmitter ligand to the GABAAα1 receptor causes a conformational
change, dimerization, and trans-autophosphorylation of trkB on conserved tyrosine residues.
Effector proteins can dock on trkB tyrosine residues and trigger downstream signaling cascades
such as transcription activation. Alterations of trkB signaling is detrimental to synaptic plasticity
and survival of neurons. For example, downregulated transcription of GABAAα1 reduces
calcium signaling, which we know is necessary for an action potential.38,42 The GABAAβ
proteins are also part of a ligand-gated ionic channel family and are regulated in the same
manner as GABAAα. After translation, proteins encoded from GABRB receptor genes play an
important role in the formation of a functional inhibitory GABAergic synapse in addition to
mediating synaptic inhibition through GABA-gated ion channels.43 Our laboratory has
previously demonstrated that gene expression using laser captured microdissected pyramidal
neurons for the trkB gene (NTRK2) was significantly lower in ASD anterior cingulate cortical
neurons as compared to TD cells.44 Similar studies have shown the importance of genetic
regulation and precise function of the BDNF-NTRK2 signaling cascade for axonal and dendritic
growth as well as a functional GABAergic synapse.45–47 The BDNF signaling cascade of PI3K
activates the mammalian target of rapamycin (mTOR) protein that influences protein translation
from messenger Ribonucleic Acid (mRNA). The dysregulation of the PI3K-Akt-mTOR pathway
can disrupt protein synthesis at neuronal synapses possibly associated with ASD given that
mature signaling pathways are responsible for development of the cortex, synaptic function, and
synaptic plasticity.47

19

Using a mouse model of Mecp2, a gene encoding for a protein that modifies chromatin to
regulate gene expression and is highly abundant in the brain, knockdown it was found that
dendritic atrophy occurred with Mecp2 knockdown and could be rescued by an overexpression
of BDNF.48,49 Hippocampal neurons infected with an adenovirus vector expressing the inactive
trkB isoform was used to demonstrate that presynaptic expression of Tyrosine kinase lacking
isoform (T1) inhibited BDNF enhancement of synaptic transmission by the inhibition of specific
tyrosine kinase phosphorylation. This study shows that the dimerization and autophosphorylation
of the kinase domain in Trk receptors is essential for receptor function, the activation of
signaling pathways.45,46 BDNF is implicated in multiple neurodegenerative disorders due to
trkB’s ability to regulate expression of genes involved in neural plasticity and cell survival.
Taken together these studies highlight the role of BDNF in the connectivity of neuronal networks
that is required for synaptic plasticity. BDNF-TrkB signaling is a potential pathway that could be
disrupted in excitatory and inhibitory neurons of the ACC in ASD. Additionally, BDNFimmunohistochemistry specifically in frontal cortical neurons was notably increased in TD tissue
as compared to ASD tissue.50 Studying regulation of the GABAergic receptors leads researchers
to believe the need for precise and regulated BDNF expression in the cell is necessary to
establish connectivity of the neuronal network as dysregulation leads to dysfunctional synapses.
These findings suggest BDNF-TrkB deficiencies in both a cell- and region-specific pathology in
ASD; thus, providing further support for a need to identify the precise source of the excitatory to
inhibitory imbalance in ASD.
Proinflammatory Disturbances Observed in ASD Etiology
Neuroinflammatory mediators are a protective mechanism that could impact GABAergic
and glutamatergic signaling. Glial cells are important neuroinflammatory cells in the brain.
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Microglia are specialized glial cells that function as macrophages in the CNS and release
cytokines that can directly impact organization and function of dendritic spines on glutamatergic
and GABAergic neurons.51 Proinflammatory and immunoinflammatory disturbances observed in
the etiology of ASD have led researchers to investigate cytokines. Thirty ASD and age/gendermatched controls used an ELISA assay to show that blood serum levels of visfatin, resistin, and
TNF-alpha were significantly higher in ASD children.52 Our laboratory recently demonstrated
altered gene expression levels of anti- and pro-inflammatory signaling molecules in both gray
matter (GM) and white matter (WM) tissue in the ACC implicating a possible unique cytokine
profile that may be associated ASD.53 PARP1, (Poly(ADP-ribose) polymerase 1) a protein
activated by DNA damage, plays an important role in the regulation of these anti- and proinflammatory mediators by controlling gene expression using transcriptional regulation to act as
a coactivator/corepressor and to stabilize mRNA of chemokines and cytokines after
transcription.54 Altered expression of neuroinflammatory mediators may be associated with
GABAergic changes.
Conclusion of GABA Dysfunction
A growing body of literature supports GABA dysfunction in ASD that may be related to
the BDNF-NTRK2 signaling pathway, but little has come from postmortem literature of donors
that were diagnosed with ASD. Evidence of the excitatory and inhibitory neuronal imbalance in
ASD includes blood plasma levels and fMRI studies that show differences when compared to TD
which can be used in the future as both a diagnostic tool and a novel treatment.55 Polymorphisms
in genes GABRβ3, GRIN2B, and CPLX1 have been found to be significantly associated with
ASD, as well as CNVs providing more evidence for the dysregulation of GABA genes in
afflicted patients due to their appearance in disorders such as fragile X and tuberous sclerosis
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complex that are highly associated with ASD.9,10,12,16 In epilepsy, a condition found to co-occur
with ASD, drugs enhancing GABAergic action, phenobarbital and bumetanide, were found to
reduce seizure effects by counterbalancing glutamatergic excitation and restoring E/I crosstalk.24 Alterations of the BDNF-TrkB pathway, such as the inability to phosphorylate the TrkB
receptor, that may affect GABAergic signaling have been shown in glutamatergic neurons in
ASD.44 Pathology and pathophysiology studies from those directly affected with ASD are vital.
The study here will seek to identify distinct synaptic pathology that could be related to the
excitatory/inhibitory theory of ASD in the ACC.
Hypothesis
The proposed studies will use postmortem brain tissue from typically developing (TD)
age-matched brain donors and donors that were diagnosed with ASD to determine if synaptic
pathology related to GABAergic neurotransmission is found in the ACC. Specifically, laser
capture microdissection (LCM) will be used to isolate pyramidal neurons in the ACC to
determine alterations in gene expression of GABAergic receptors. Immunoblotting will be used
to determine changes in synaptic protein expression in the ACC of punch-dissected tissue
homogenates. These experiments were created to satisfy the hypothesis that the synaptic
pathology associated with GABAergic transmission is found in ASD.
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CHAPTER 2. MATERIALS AND METHODS
Brain Tissue
Postmortem human brain tissue from the frontal cortex (BA10) and ACC (BA24) from
donors with ASD and age-matched typically developing (TD) control specimens were obtained
from Autism BrainNet and NeuroBioBank. Tissues were matched a priori by the brain bank
using medical records, clinical information, and postmortem tissue information including age,
postmortem interval (PMI), and RNA Integrity Number (RIN) (Table 1).56 Cause of death for TD
control donors included drowning and trauma. The cause of death for ASD donors included:
asphyxia, trauma, ketoacidosis, and bowel obstruction. This information has not been added to
Table 1 to ensure the identify of donors remains anonymous. ASD specimens have confirmed
diagnosis by meeting diagnostic criteria provided by a team of clinicians that used the autism
interview and medical records when available to confirm ASD diagnosis. These studies use
postmortem human tissue and are not considered human research by the ETSU institutional
Review Board.56
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Table 1. Subject Demographic Information for Donor Tissues Used for Immunoblotting
Pair

ID

Gender

1

AN14757

M

2

AN07176

M

21

7.6

29.9

3

AN07444

M

17

6.1

30.8

4

5408

M

6

5.8

16.0

5

4848

M

16

7.6

15.0

6

5342

M

22

8.1

14.0

7

5079

M

33

7.3

16.0

8

m3231m

M

37

7.4

24.0

9

4590

M

20

6.8

32.9

WB,
PCR
WB

11

1105

M

16

7.8

28.9

WB

12

12137

M

31

7.3

26.2

WB

14

4670

M

4

6.2

17.0

WB,
PCR

20.583
2.87

7.15
0.22

22.66
2.01

Mean
SEM

Age
RIN
Control
24
7.8

PMI

Assay

Tissue

21.3

WB,
PCR
WB

BA10,
BA24
BA10,
BA24
BA10,
BA24
BA10,
BA24
BA10,
BA24
BA10,
BA24
BA10,
BA24
BA10,
BA24
BA10,
BA24
BA10,
BA24
BA10,
BA24
BA10,
BA24

WB,
PCR
WB,
PCR
WB,
PCR
WB,
PCR
WB

ASD
1

AN04166

M

24

8.1

18.5

2

AN03935

M

19

7.0

28.1

3

AN02987

M

15

6.7

30.8

4

5144

M

7

8.0

3.0

5

5302

M

16

6.6

20.0

24

WB,
PCR
WB
WB,
PCR
WB,
PCR
WB,
PCR

BA10,
BA24
BA10,
BA24
BA10,
BA24
BA10,
BA24
BA10,
BA24

6

5176

M

22

7.1

18.0

7

5297

M

33

7.1

50.0

8

5027

M

37

7.7

26.0

9

4999

M

20

7.0

16.1

WB,
PCR
WB

11

5403

M

16

6.6

23.7

WB

12

11989

M

30

7.7

23.2

WB

14

5308

M

4

7.0

21.0

WB,
PCR

20.250
2.83

7.2
0.15

23.2
3.18

Mean
SEM
RIN, RNA integrity number

WB,
PCR
WB

BA10,
BA24
BA10,
BA24
BA10,
BA24
BA10,
BA24
BA10,
BA24
BA10,
BA24
BA10,
BA24

WB, Western Blotting

Tissue Preparation and Sectioning
Frozen tissue blocks of BA24 and BA10 were sectioned using a cryostat microtome
(Leica CM3050S) at -20oC. Tissue blocks were left to thaw inside the Leica for one hour prior to
sectioning and Optimal Cutting Temperature compound (Sakura, Tissue-Tek O.C.T. Compound,
cat# 62550-01) was used to adhere the tissue to the mounting block. Section thickness varied
including 10 µM for laser capture microdissection experiments and 40 µM sections for punch
dissection homogenates. Laser capture microdissection, 10 µM, sections were placed on
superfrost plus microscope glass slides (Fisherbrand, cat# 12-550-15), labeled, and stored in
microslide black boxes at -81oC. Additionally, brain tissue was punch-dissected, 40 µM
thickness, using a 3.5 mm trephine. Tissue punches were placed in 1.5 mL Eppendorf tubes and
stored at -81oC until use. Tissue pairs of ASD and TD were prepared and stored together to
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ensure identical handling. The central point of the tool was placed over layer three of the
neocortex in both BA10 and BA24 when punch-dissecting.
Laser Capture Microdissection
Ten-micron thick sections were used for Laser Capture Microdissection (LCM). Cells
were identified using a Cresyl violet stain from the Applied Biosystems (Thermo Fisher
Scientific, Arcturus™ HistoGene™ Staining Solution, Cat# 00728573). In brief, frozen human
postmortem brain tissue sections were fixed, rehydrated, incubated with Cresyl violet for 45
seconds, and dehydrated with 75% EtOH, 95% EtOH, and 100% EtOH for 30 seconds each, and
left in Xylene for 5 minutes. Once the tissue was dry, the section is desiccated for proper
transport to the laser capture microdissection instrument which uses infrared laser technology to
capture the neuronal soma. LCM was performed using an ArcturusXT instrument (Life
Technologies AXT 2142) to visualize and capture pyramidal neurons (Figure 1A) from the ACC
or BA24 at 60X magnification. The Arcturus XT software tracks the number of cells during a
single capture, but the captured cell type and neocortical layer is dependent upon morphological
identification and neuronal size measured by the user. Pyramidal neurons are triangular in shape
and get larger as neocortical layer gets deeper, which is visible on tissue by observing neuron
density. Pyramidal neurons in neocortical layer 2 are approximately 15-20 µm in width. Neurons
with other cell bodies, astrocytes or glia, nearby were not chosen to reduce other neuronal
mRNA from capture. Infrared (IR) laser technology is used to capture approximately six
hundred neurons onto CapSure macrocaps (Life Technologies, Arcturus™ CapSure HS LCM
Starter Pack, cat# 10284-05). The tissue is manually inspected at a higher power to ensure that
the cell has been lifted onto the cap (Figure 1B). Lastly, the cap can be visualized at 20X
magnification in the QC station and the number of cells counted to compare against actual
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number of cells identified by the Arcturus and lifted from tissue (Figure 1C). After the capture is
complete, the cap is visualized under a dissecting microscope to remove any excess tissue
attached by scraping it off with a syringe needle. The cap, now with only selected neuronal cells
attached, is placed in a 0.5 mL tube containing 55 µL of extraction buffer solution (Thermo
Fisher, Arcturus™ PicoPure™ RNA Isolation Kit, cat# 00809988) and incubated in a 42oC water
bath for 30 minutes. Cells are then removed from the water bath, the extraction buffer is
centrifuged to the bottom, and the Eppendorf tube is stored at -20oC until used to extract purified
RNA.
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Figure 1. Images from ArcturusXT of human BA24 tissue. A) Pyramidal neuron, circled in red,
are imaged from the ArcturusXT instrument at 60X magnification in the ACC of postmortem
human brain tissue in Neocortical layer 2. B) ACC tissue post cell soma capture. C) Captured
pyramidal cells visualized on CapSure Macrocap to ensure complete capture.
RNA Purification
RNA extraction from laser captured cells was performed with the Arcturus™ Picopure™
RNA Isolation Kit (cat# KIT0204, Thermofisher, Waltham, MA) with a column-based binding
and on-column DNase treatment. Columns from the kit were first conditioned with 250 μl of
conditioning buffer (CB) at room temperature for 5 minutes. The columns were then centrifuged
at 16,000g for 1 minute and the flow-through, CB, was discarded. 55 μl of 70% EtOH, equal to
the amount of extraction buffer, was added to the column along with the extraction buffer and
the mixture is centrifuged at 100g for 2 minutes followed by 16,000g for 30 seconds. For
maximum binding, the flow-through can be placed back inside the column and the centrifugation
repeated. After RNA is bound to the column beads, 100 μl of wash buffer 1 (W1) is added and
centrifuged at 8,000g for 1 minute. The on-column DNase treatment was prepared in a separate
tube with reagents as follows: 5 μl DNase 1 and 35 μl Buffer RDD, both from the Qiagen
RNase-Free DNase Set (Qiagen, cat# 79254). DNase treatment was gently mixed by inversion of
the Eppendorf tube and 40 μl was pipetted on top of the column beads and left to incubate for 15
minutes at room temperature. 40 μl of W1 was added to the column at the end of 15 minutes and
centrifuged at 8,000 x g for 15 seconds. For thorough washing, 100 μl of wash buffer 2 (W2) was
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added to the column and centrifuged at 8,000 x g for 1 minute and then repeated with fresh W2
and centrifuged at 1,000 x g for 1 minute and 16,000 x g for 1 minute. After the final
centrifugation at 16,000 x g twice for 2 minutes. At this time, the column is placed into a fresh
0.5 ml Eppendorf tube where 16 μl of elution buffer is added and let incubate for 5 minutes at
room temperature. This is centrifuged, this sample can be reverse transcribed into cDNA. Forty
micron (40 µm) thick sections are used for punch dissected positive control samples. To purify
RNA from punch tissue, 200 μl of extraction buffer and 200 μl of 70% EtOH are added while the
Eppendorf tube containing the tissue is still in the -80°C freezer. The tubes can then be removed,
placed on ice, and vortexed to ensure the tissue has dissolved into the liquid mixture. The same
protocol as above is used to purify RNA except 18 μl of elution buffer is used instead of 16 μl.
cDNA Synthesis
RNA samples were reverse transcribed into cDNA using the Superscript III kit (Life
Technologies, First-Strand Synthesis SuperMix for qRT-PCR, cat# 11752-050) using oligodTs
and random hexamer primers. Each cDNA sample contains a mixture of 10 μl 2x RT Reaction
Mix, 2 μl RT enzyme mix, and 8 μl purified RNA. This mixture is run on a Bio-Rad
Thermocycler (Bio-Rad, T100™ Thermal Cycler, 1861096) for 10 minutes at 25°C, 30 minutes
at 50°C, and 5 minutes at 85°C. At step four the thermocycler pauses and 1 μl RNase H is added
to the sample followed by a 20-minute incubation at 37°C at which time the cDNA is complete
and can be stored at -20°C until analysis (Appendix Table 1).
Primer Creation
Primers annealing to GABAergic receptor genes expressed in the LCM pyramidal
neurons were created by using NCBI Gene to obtain all variants for a specific gene in Homo
sapiens. All variants were compiled into a word document and the shortest variant was used to
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create the primers and then checked with NCBI blast to ensure the spanned exons were present in
each gene variant. A folding assay was performed with chosen sequences using the mFold
webserver, free on the list serve by The RNA Institute College of Arts and Sciences University
of Albany, to identify folding patters for mRNA sequences at 61°C and 65°C. Ionic conditions for
Magnesium and Sodium were changed to 2 mM and 50 mM respectively. Both sequences were
analyzed for secondary structure formation at the two temperatures. Next, the sequence was
removed of any sequence identifiers using the Bio-Web sequence cleaner. The sequence was
then loaded into the Integrated DNA Technologies (IDT) PrimerQuest software to identify
potential 100 bp sequences. Next, potential primer sequences were analyzed for gene similarity
to other genes in the human genome. If the sequence was 66% or more that potential primer was
disregarded. Amplicon size was set to 90-120 base pairs and the primers selected spanned at least
one exon junction to ensure mRNA binding. Two primers were ordered for every gene, when
possible, but only the best primer was used for gene expression studies (Appendix Table 2). In
some cases, the primer was not made through IDT and was instead ordered directly from Qiagen
using their proprietary Quantitect software as noted in Appendix Table 2.
PCR Amplification
Primers were optimized for annealing temperature and primer concentration using punch
dissected sample, BA24, for enzymes used in downstream assays. The annealing temperature is
the temperature at which the enzyme and primer work best together to amplify cDNA strands.
Typically, the annealing temperature is 5°C below the primers melting temperature and this was
visualized with The Agilent Tape Station 2200 (Agilent Technologies C295A) using at least 5
temperatures that ranged from 52o to 65o Celsius. Primer concentration was optimized at the
optimal temperature. Primer concentration is important to optimize to conserve reagents as well
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as to confirm only one amplicon is amplifying. Complete optimization details, temperature, and
primer concentration are outlined in Appendix Table 3.
Primers were also optimized for laser captured parameters of cycle. A nested PCR
method was used to amplify cell captures so that the Stratagene quantitative PCR thermocycler
could detect amplification. Pre-amplification cycles were chosen by determining which cycle
number gave a reliable threshold count using forty cycles for quantitative-RealTime-PCR (q-RTPCR) run. The mRNA captured from 500 Pyramidal neurons in BA24 of tissue donors that had
been converted to complimentary DNA (cDNA) was diluted 6 μl H2O: 2 μl cDNA to conserve
tissue. Pre-amplification reactions included 2X master mix enzyme with dNTPs and magnesium
(Appendix Table 4), water, and gene specific primer (10X) in a volume of 11.5 μl. Template
cDNA from each donor (approximately 600 cells) was added at a constant volume of 0.5 μl of
LCM cell cDNA to each reaction. Duplicate reactions were performed for each sample. Preamplification thermocycler parameters were optimized for each gene specific primer with a taqbased enzyme (Appendix Table 3). The pre-amplified reactions were used in combination with
q-RT-PCR reactions to analyze target genes (GABRA1, GABRA4, GABBR1) in ASD and TD
brain donor laser capture samples. Gene selection rationale is outlined in Appendix Table 5. The
quantitative PCR reaction mix included water, 10X gene specific primer, and 2X Power-up
syber-based enzyme (Appendix Table 4) in a volume of 17 μl; afterwhich, 1μl of each preamplification reaction is added to reaction mix. Each pre-amplification target was performed in
duplicate resulting in four QPCR reactions for each sample. Two positive control reactions of 1
μl punch cDNA and two blank wells with 1 μl of water were included for each gene. Reaction
parameters were optimized using PowerUp enzyme at 40 cycles on an Agilent Stratagene
Mx3000 (Agilent Technologies, Stratagene serial#DE10900784). Each target gene was
31

normalized to two housekeeping genes (18S ribosomal RNA and Beta-2-Microglobulin) during
gene analysis.
Immunoblotting
Brain tissue was homogenized with ten seconds of sonication using Tris-EDTA buffer
supplemented with protease inhibitors. Protein assays were performed with tissue homogenates
using the Micro BCA™ Protein Assay kit (ThermoScientific, cat# SI252807). Bovine serum
albumin (BSA) standards were diluted in phosphate buffer saline (PBS) ranging from 200 µg to
2 µg. Dilutions of samples (100-fold and 25-fold) were created using PBS to insure the same
refractory index as dilution of standards. Assay with BSA standards and tissue homogenate was
incubated at 57°C for one hour and then read using a plate reader at 562 nm wavelength for
index determination. Protein homogenate was mixed at a 1:4 dilution with Laemmli/BetaMercaptoEthanol (βME) loading buffer and heated at 95oC for 5 minutes to be stored at -80oC
until use. From the protein assay, the protein homogenates were standardized to twelve
micrograms of protein and diluted to make 40 μl total concentration. For each gel, 10 µL of a
Precision Protein standard ladder (Bio-Rad, Protein™ Dual Color Standards, cat# 161-0374) was
added to demonstrate the molecular weight in kilodaltons. Eleven matched ASD/TD pairs, the
protein homogenates, were loaded as singlets on two different 10% SDS-polyacrylamide gels
(BioRad, Mini PROTEAN TGX Gels, cat# 456-1084), and 3 wells containing 25 μg, 12.5 μg,
and 6.25 μg of protein were loaded for use as a standard. Gels were subjected to electrophoresis
for one hour at 100V. Denatured proteins captured in the gel were then transferred onto a
nitrocellulose membrane (BioRad, Nitrocellulose Membranes 0.45 µm, cat# 1620115). The
nitrocellulose membrane is thoroughly washed and is stained with Ponceau S (SIGMAALDRICH, 0.1% Ponceau S, 5% acetic acid, cat #SLCB3855) for later use as a standard and to
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confirm successful protein transfer. Ponceau S is removed using 1X PBS-Tween20 (TBST).
Following Ponceau-S stain, the nitrocellulose membrane is blocked in 5% skim milk solution for
one hour. Protein bound to the membrane are probed with primary antibodies at different
concentrations: Spinophilin (1:1,000), PSD95 (1:1,000), IGF1R (1:1,000), mTOR (1:1,000),
Aggrecan (1:1,000), PARP1 (1:1,000), CPLX1 (1:1,000), and GapDH (1:10,000) (Table 2 and
Appendix Table 6) overnight at 4oC with rotation. Post incubation, membranes were washed
three times with 1X PBS-Tween20 for ten minutes and followed with a secondary antibody
incubation with either anti-mouse (1:10,000) or anti-rabbit (1:5,000) horseradish peroxidase
(HRP)-conjugated secondary antibody (GE Healthcare, ELC™ Anti-Mouse IgG, HRP linked
whole antibody, cat#4950492) (GE Healthcare, ELC™ Anti-Rabbit IgG, HRP linked whole
antibody, cat# 17065614) at room temperature. Lumagen ECL ultra substrate (Lumagen,Inc,
Lumagen ECL Ultra Solution A and B, cat# TMA-100) is used at a 1:10 dilution for each part
for visualization using the BioRad ChemiDoc machine (BioRad, ChemiDoc™ Imaging System).
Images are obtained using the BioRad ChemiDoc and analyzed by the BioRad ImageLab
software to quantify protein band concentration. Next, bound antibodies were removed from
membranes using a mild stripping buffer, pH 2.2, for 12 minutes (Abcam). After stripping, the
membrane was thoroughly washed, blocked using 5% milk for one hour and re-probed with a
different primary antibody overnight (Appendix Table 7). The order of antibody incubation is as
such: Day 1 Spinophilin & CPLX1, Day 2 IGF1R & mTOR, Day 3 PSD95, Day 4 PARP1, Day
5 Aggrecan, Day 6 GapDH. Some Antibodies were able to run together because of the molecular
size (in kilodalton) of their target and incubation solutions outlined in Table 2 and Appendix
Table 7. All buffers used for immunoblotting are found in Appendix Table 8. For protein band
analysis, means and standard deviations were calculated for all band densities including
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Spinophilin, CPLX1, mTOR, IGF1R, PSD95, PARP1, and Aggrecan for immunoblotting data.
Ratios were calculated for each target protein using a housekeeping protein (GAPDH).

34

Table 2. Proteins Analyzed for Immunoblotting
Protein
Spinophilin

PSD-95

IGF1R
mTOR
Aggrecan
PARP1

CPLX1

GapDH

Job in VIVO
Modulate glutamatergic
synaptic transmission &
dendritic morphology
Postsynaptic scaffolding
protein: clusters glutamate
receptors and organizes
signaling complexes
Receptor for Insulin-like Growth
Factor 1. Regulates cell growth
and proliferation
Cell survival and dendritic
plasticity
Organization of extracellular
nets between neurons
Regulator of NF-κB by
promoting nuclear translocation
Prevent SNAREs from releasing
neurotransmitters until an
action potential arrives at the
synapse
Glycolytic enzyme that
catalyzes the conversion of
glyceraldehyde 3-phosphate to
1,3-diphosphoglycerate

Kilodalton
130 kDa

95 kDa

90 kDa
289 kDa
150 kDa
113 kDa

18 kDa

37 kDa

Statistical Analysis
All data was subjected to tests for normality. Additionally, all data was examined for
outliers using both a Grubb’s test and a ROUT test. Analysis for differences in threshold cycle
used the Livak and Schmittigen method for delta delta Ct values.57 If data was found to be
normally distributed, an unpaired two-tailed Student’s t-test was used to compare data between
ASD and TD donors for immunoblotting data. If data failed tests for normality, a Mann-Whitney
test was used to assess statistical analysis between groups. All correlations were performed with
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the linear correlation analysis producing a Pearson R-value including those between target
expression values and age, PMI, and RIN. Any significant correlation that was found was
subjected to a univariate analysis between the groups with the variable used as a confound.
Lastly, paired testing was conducted to validate previous statistical methods and shown in the
appendix. All data analyses were performed using Graphpad Prism version 9. Statistical
significance was determined as a p-value less than 0.05.
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CHAPTER 3. RESULTS
Touchdown Assay used for Laser Capture Studies
Touchdown PCR assays were preformed to pre-amplify the desired amplicon for QPCR
analysis of GABAergic receptors. This type of assay is novel in the literature for laser capture
studies. Extraction of mRNA from laser capture microdissected pyramidal cells (500 cells) in
BA24 yields small quantities of cDNA. Touchdown assays for varying cycles (Table 3) and
concentration gradients (Table 4) were performed for every gene (GABRA1 shown) that the
small amounts were capable of demonstrating reliable threshold scores, the cycle at which linear
amplification of cDNA is detected by the Agilent machine, during q-RT-PCR amplification.
Representative graphs are shown to demonstrate that genes did exhibit a linear correlation
between cycle threshold with preamplification threshold (Figure 2 A) and concentration (Figure
2 B). GABRA4 and GABBR1 threshold tables and graphs are outlined in Appendix Tables 9-12
and Figures 1-2.
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Table 3. Cycle Optimization for GABRA1 with HotStar Enzyme
65°C, 58° C w/ HotStar
2/17/2021
GABRA1
Threshold
28.32
19
17.42
22
15.61
25
9.0
Punch
36.74
Blank
23.86
+ Control
Table 4. cDNA Template concentration check for Threshold
65° C, 58° C w/ HotStar
3/17/2021
GABRA1
Threshold
28.49
Full
31.71
Half (1:2)
39.64
Fourth (1:4)
16.8
Punch
0
Blank
25.39
+ Control

Figure 2. Graphs correlating with cycle optimization and template concentration tables. Panel A
denotes the preamplification cycle used for expression of GABRA1. The y-axis is the threshold
cycle at which the product approached linear amplification. The x-axis is the number of cycles
the cDNA template was pre-amplified using standard PCR. Panel B denotes template
concentration to assure cDNA would reach threshold. The y-axis is the threshold cycle at which
the product approached linear amplification. The x-axis is the initial cDNA template that was
used at no dilution (1), 1:2 dilution and 1:4 dilution.

Gene Expression Differences in ASD Pyramidal Cells
GraphPad Prism version 9 software was used to analyze QPCR data obtained from
Agilent Stratagene Mx3000. GABAergic receptor genes including GABRA1, GABRA4, and
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GABBR1 were amplified in BA24 pyramidal neurons. Analysis for differences in threshold
cycle used the Livak and Schmittigen method for delta delta Ct values. Genes were analyzed by
an unpaired Student’s t-test using ASD and TD brain donors. It was found that no significant
differences in gene expression of any of the GABAergic receptors in BA24 pyramidal neurons
were present when comparing ASD and TD brain donors (Figure 3 Panel A-C). However, it
should be noted that increased expression trends in GABRA4 (Figure 3B) and GABBR1 (Figure
3C) expression are apparent in ASD when compared to TD brain donors.
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Figure 3. Unpaired analysis of q-RT-PCR data Panel A) Gene Expression of
GABRA1 was determined in human postmortem tissue from anterior cingulate, BA24 (N=7)
laser capture microdissected brain tissue from TD control tissue (white bars) and ASD tissue
(black bars) using the Livak/Schmittagen delta delta Ct method for QPCR. GABRA1 gene
expression was normalized to the gene expression of 18S ribosomal RNA and beta-2microglobulin. An unpaired Student’s t-test was used to determine statistical significance with
p<0.05. Panel B) GABRA4 (N=5) and Panel C) GABBR1 (N=6) analysis were performed using
the same parameters.

Immunoblotting in the ACC
GraphPad Prism 8 software was used to analyze immunoblotting data obtained
from ChemiDoc ImageLab software. Student’s unpaired t-tests determined that no significant
differences in synaptic protein expression for Spinophilin, CPLX1, mTOR, IGF1R,
PSD95, or PARP1 were found in gray matter from BA24 (anterior cingulate cortex) or BA10
(frontal cortex) between ASD and TD brain tissue homogenates (Figure 4). While some proteins
gave very small concentration differences between the donors, BA10: CPLX1, PSD-95
(Appendix Figure 3 B, E) BA24: Spinophilin, PSD-95, and PARP1 (Appendix Figure 4 A, E, F),
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others seemed to have no correlation trends at all and concentrations varied drastically between
matched donors, BA10: IGF1R and PARP1 (Appendix Figure 3 D and F) BA24: CPLX1 and
IGF1R (Appendix Figure 4 B and D). One noticeable correlation occurs in BA10 Spinophilin
which shows a downward trend in ASD (Figure 4A).
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Figure 4. Unpaired analysis of Immunoblotting data. Panel A) Protein Expression of
Spinophilin was determined by immunoblotting in human postmortem tissue from frontal cortex,
BA10 (N=11), and anterior cingulate, BA24 (N=11) punch-dissected brain tissue from TD
control tissue (gray bars) and ASD tissue (black bars). Spinophilin protein expression was
normalized to the protein expression of GAPDH. An unpaired Student’s t-test was used to
determine statistical significance of p<0.05. Panel B) CPLX1, Panel C) mTOR, Panel D)
IGF1R, Panel E) PSD95, and Panel F) PARP1.

Correlations of Demographic Information
The brain tissues that are used in this study are matched by age, RIN and PMI a-priori by
the tissue brain banks. The potential effects were examined by using correlations to compare
protein and gene expressions to matching factors in the groups. Age was not significantly
different between the ASD and TD group (Mean: 20.58, 20.25 SEM: 2.87, 2.83). Significant
correlations between protein expression levels for spinophilin, mTOR, IGR1R, PSD 95 and
PARP1 with age were noted in the anterior cingulate or BA24 (Table 5). Interestingly, none of
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the protein expressions demonstrated significant correlations with age in control donors from the
frontal cortex or BA10 only in the combined donor groups for IGF1R and PARP1 (Table 6).
Neither RIN (Mean, SEM) nor PMI (Mean, SEM) demonstrated differences between ASD and
TD donor groups (Table 1). Although RIN is an important factor in molecular studies, it can be
used as a global factor of tissue quality. RIN values did correlate with spinophilin, mTOR,
PSD95, and PARP1 in control donor tissue (Table 5). There were no correlations between PMI
with any protein expression level in any group (Table 5-6). Additionally, no gene expression
levels of any of the GABAergic receptors correlated with age, RIN or PMI (Table 7). Univariate
analysis was performed for any protein that demonstrated a significant correlation with a
matching factor. No effects of the factor were found for any protein between ASD and TD donor
tissues (Table 8). For completeness, a Student’s paired t-tests were used to determine no
significant differences could be found for Spinophilin, CPLX1, mTOR, IGF1R, or PSD95 in
grey matter from BA10 or BA24 in the same eleven ASD-TD pairs (Appendix Figure 2-3).

43

Table 5. Pearson Correlations for Western Blotting Protein Expression Levels vs Potentially
Confounding Variables in BA24. *p<.05, **p<.01
All donors combined
SPIN
CPLX
mTOR
IGF1R
PSD95
PARP1
Age Pearson r
-.6121
-.6453
-.4646
.6916
-.5154
-.7105
Sig. (2-tailed)

.003**

.0012**

.0294*

.0007**

.0141*

.0002**

N
Pearson r
Sig. (2-tailed)
N
Pearson r
Sig. (2-tailed)
N

22
-.2720
.2208
22
-.0104
.9633
22

22
-.3365
.1257
22
-.2909
.1890
22

22
-.0601
.7904
22
-.4272
.0474*
22

20
.3744
.1039
20
-.1125
.6367
20

22
-.2157
.3349
22
-.1537
.4946
22

22
-.2808
.2056
22
-.4089
.0588
22

Control donors
Age Pearson r
Sig. (2-tailed)
N
RIN Pearson r
Sig. (2-tailed)
N
PMI Pearson r
Sig. (2-tailed)
N

SPIN
-.7945
.004**
11
-.6795
.0215*
11
.2597
.4407
11

CPLX
-.5263
.0963
11
-.4586
.1559
11
.2871
.3920
11

mTOR
-.6691
.0244*
11
-.6101
.0462*
11
-.2635
.4337
11

IGF1R
.7922
.006**
10
.4403
.2028
10
-.3226
.3633
10

PSD95
-.6039
.0491*
11
-.6752
.0226*
11
.4293
.1876
11

ASD donors
Age Pearson r
Sig. (2-tailed)
N
RIN Pearson r
Sig. (2-tailed)
N
PMI Pearson r
Sig. (2-tailed)
N

SPIN
-.4935
.1229
11
.1394
.6827
11
-.1306
.7019
11

CPLX
-.8302
.0016**
11
-.1695
.6184
11
-.6854
.0199*
11

RIN

PMI

mTOR
-.3316
.3192
11
.5434
.0840
11
-.5018
.1158
11
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IGF1R
.6260
.0528
10
.2950
.4080
10
.0703
.8470
10

PSD95
-5138
.106
11
.1012
.7672
11
-.3428
.3021
11

PARP1
-.8478
.001**
11
-.7982
.0032**
11
.1554
.6483
11

PARP1
-.6323
.0368*
11
.2236
.5087
11
-.6584
.0276*
11

Table 6. Pearson Correlations for Western Blotting Protein Expression Levels vs Potentially
Confounding Variables in BA10. *p<.05, **p<.01
All donors combined
SPIN
CPLX
mTOR
IGF1R
PSD95
PARP1
Age Pearson r
.3171
.2381
-.3619
.4674
.2786
-.4547
Sig. (2-tailed)

.1311

.2859

.0823

.0213*

.2343

.0335*

N
Pearson r
Sig. (2-tailed)
N
Pearson r
Sig. (2-tailed)
N

24
.2125
.3189
24
-.1906
.3724
24

22
.1507
.5032
22
-.0005
.9963
22

24
-.3687
.0763
24
.1850
.3868
24

24
.3012
.1526
24
-.0868
.6865
24

20
.0589
.8049
20
-.3052
.1907
20

22
-.2827
.2025
22
-.0482
.8313
22

Control donors
Age Pearson r
Sig. (2-tailed)
N
RIN Pearson r
Sig. (2-tailed)
N
PMI Pearson r
Sig. (2-tailed)
N

SPIN
.2877
.3645
12
.1164
.7186
12
-.4498
.1423
12

CPLX
-.0126
.9706
12
-.1046
.7595
11
-.2417
.4740
11

mTOR
-.4918
.1043
12
-.4051
.1915
12
.1714
.5884
12

IGF1R
.5401
.0698
12
.3968
.2015
12
-.5734
.0513
12

PSD95
.3255
.3588
10
-.0558
.8783
10
.0386
.9156
10

ASD donors
Age Pearson r
Sig. (2-tailed)
N
RIN Pearson r
Sig. (2-tailed)
N
PMI Pearson r
Sig. (2-tailed)
N

SPIN
.3622
.2473
12
.4183
.1760
12
-.0268
.9339
12

CPLX
.5084
.1103
11
.5444
.0834
11
-.2085
.5383
11

RIN

PMI

mTOR
-.2277
.4767
12
-.2987
.3457
12
.2314
.4692
12
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IGF1R
.4226
.1711
12
.1786
.5786
12
.1868
.5611
12

PSD95
.2461
.4931
10
.1624
.6539
10
-.4440
.1986
10

PARP1
-.5107
.1084
12
-.3186
.3397
11
-.3895
.2364
11

PARP1
-.4025
.2197
11
-.2632
.4342
11
-.2076
.5401
11

Table 7. Pearson Correlations for LCM Gene Expression Levels vs Potentially Confounding
Variables in BA24. *p<.05, **p<.01
All donors combined
Age Pearson r
Sig. (2-tailed)
N
RIN Pearson r
Sig. (2-tailed)
N
PMI Pearson r
Sig. (2-tailed)
N

GABRA1
.1046
.7221
14
-.09988
.7341
14
.0911
.7565
14

GABRA4A
.1311
.7181
10
-.1627
.6533
10
.0503
.8902
10

GABBR1
.0353
.9132
12
.2591
.4162
12
-.2937
.3542
12

Control
Age Pearson r
Sig. (2-tailed)
N
RIN Pearson r
Sig. (2-tailed)
N
PMI Pearson r
Sig. (2-tailed)
N

GABRA1
.1746
.7081
7
-.4440
.3183
7
.4544
.3057
7

GABRA4A
-.2493
.6858
5
.08075
.8973
5
-.3608
.5508
5

GABBR1
.1732
.7428
6
.6783
.1386
6
-.2184
.6776
6

ASD
Age Pearson r
Sig. (2-tailed)
N
RIN Pearson r
Sig. (2-tailed)
N
PMI Pearson r
Sig. (2-tailed)
N

GABRA1
.0617
.8954
7
.4898
.2645
7
-.1021
.8276
7

GABRA4A
.2665
.6647
5
-.2064
.7391
5
.0494
.9370
5

GABBR1
-.0524
.9214
6
-.1860
.7242
6
-.3233
.5319
6
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Table 8. Univariate Analysis with Potentially Confounding Variables for Western Blotting in
BA24 that Demonstrated a Significant Correlation in Control Groups. *p<.05, **p<.01. <.05,
**p<.01.
Variable
Age Between group
Levene’s Test
N
RIN Between Group
Levene’s test
N

SPIN
.724
.034
11
.829
.078
11

CPLX
.109
.373
11

11

mTOR
.521
.383
11
.806
.200
11

IGF1R
.126
.878
10

10

PSD95
.513
.838
11
.608
.049
11

PARP1
.837
.064
11
.945
.098
11

Table 9. Univariate Analysis with Potentially Confounding Variables for Western Blotting in
BA10 that Demonstrated a Significant Correlation in Control Groups. *p<.05, **p<.01.
Variable
Age Between groups
Levene’s test
N

SPIN

CPLX

mTOR

12

12

12
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IGF1R
.306
.799
12

PSD95

10

PARP1
.665
.763
12

CHAPTER 4. DISCUSSION
This is the first study to use laser captured pyramidal neurons from human cingulate
cortex in ASD to examine unique cell-specific GABAergic receptor expression. In this study, qRT-PCR nested amplification was used to quantify gene expression of three different
GABAergic receptors (GABRA1, GABRA4, and GABBR1). Receptors were chosen based on
their association with the BDNF-NTRK2 pathway. The NTRK2 receptor has already been found
to be altered in this sample population by our laboratory team previously.44 Initially, ten different
GABAergic receptors were chosen for examination. The Allan Brain Atlas was initially used to
determine if transcripts for GABAergic receptors were present in the cingulate cortical region in
humans using RNA transcripts through in-situ hybridization (ISH) on postmortem human brain
tissue. While not conclusive, the ISH transcript cell morphology could be visualized through
Nissl staining in the same cortical samples in the reference brain atlas. We eventually settled on
three GABAergic receptors that had consistent expression levels that could be detected using
serial dilutions of cells laser captured from the cingulate and were known to be affected by
NTRK2/BDNF regulatory abilities. GABRA1 is downregulated by the JAK/STAT pathway that
is downstream of NTRK2, GABRA4 is upregulated by the MAPK pathway also downstream of
NTRK2, and GABBR1 is responsible for the G-protein coupled receptor function that allows
GABA neurotransmitter to bind and activate. No significant differences were found for these
three receptors. Both GABRA4 and GABBR1 did exhibit an upward expression trend albeit not
significant. It is interesting to note that GABRA4 had extremely low expression levels in the
control population. It is tempting to speculate that the gene was turned on during development of
the disorder. Additional GABAergic genes were evaluated for expression levels in pyramidal
cells excised from control donors but failed to exhibit reliable amplification and were excluded
from the study. It might be beneficial to evaluate even those GABAergic receptors that were not
reliably expressed in control tissue. They simply may be the low expressors while subjects with
the disorder may have detectable expression levels. It is inconclusive at this early stage to state
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that GABAergic receptors expression is not altered in ASD pyramidal cells. More information is
needed including studies with different GABAergic receptors and a larger sample size to
determine whether GABRA4 and GABBR1 are significantly different.
Simultaneous to laser capture studies, immunoblotting was performed to examine protein
expression differences in BA10 and BA24 brain regions in ASD and TD donors for synaptic
proteins that can impact GABAergic receptor expression and function. Some of these proteins
have been shown to be differentially expressed in other brain areas. No differences were found in
the cingulate cortex for any of the proteins examined in this study, even when adjusting for age
or RIN correlations. We were unable to corroborate the downregulation found by Western
blotting for PSD-95 or mTOR studies in the fusiform gyrus. In those studies mentioned, full
length PSD-95 and mTOR were found to be reduced when analyzing 11 ASD and 13 TD
controls in the fusiform gyrus which plays a role in object and facial recognition.58 Our study
was the first to examine spinophilin, CPLX, IGF1R and PARP1 protein expression in the
cingulate cortex when comparing ASD to TD control donors as well as ASD in general.
Unfortunately, all these proteins are expressed in multiple cell types at potentially high levels
severely limiting the conclusions of these findings. Additional studies using
immunohistochemistry to evaluate cell specific expression in pyramidal neurons and
morphological analysis such as Golgi staining would give a more complete picture of specific
GABAergic synaptic pathology in ASD.
Brain tissue that is received in our laboratory is matched by age and PMI. It was
interesting that age correlations were present in five of the six proteins for immunoblotting with
age in the control population in the ACC or BA24 but were not found in the frontal cortex or
BA10 of the exact same donors. This result was not expected because research has shown
developmental differences in gene expression from both BA10 and BA24. Not only expression
differences but also the cellular makeup of brain tissue. It was shown in postmortem brain tissue
of healthy individuals that as humans age the density of oligodendrocytes increases, which is
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important in maintaining neuronal communication.59 As the human brain develops multiple
genes are found to have altered expression. This research has been performed on both males and
females. While they found differences, the end result was the same: as the brain develops gene
expression levels change.60,61 Also, RIN correlations were found for four of the six proteins, but
again were not found in BA10 nor were there any correlations between the three GABAergic
genes examined with RIN. One thing to note, RIN has been shown to be a good indication of
mRNA quantity but cannot predict mRNA integrity. With this knowledge researchers can say
there is mRNA present in the postmortem tissue but cannot be sure the brain tissue is a good
quality, and the mRNA has remained intact.62
Limitations
This study includes several limitations that must be taken into consideration.
Experimentation was conducted with small samples sizes; however, in the ASD postmortem
literature, a study number of 12 is considered large. Additionally, it was a targeted study for a
focused number of synaptic proteins and genes to validate the current literature that is plagued
with even smaller study numbers to evaluate synaptic pathology in BA24 and BA10 regions.
Sadly, it was estimated by a leading postmortem research in the field at a recent conference that
only 150 brains are in circulation for all the ASD postmortem studies in the literature.
Additionally, the tissue pairs we received were also a range of ages from 4-37 which does not
allow for development-specific analysis. We have early, adolescent, and adult neuronal
development trajectories represented in our sample population. ASD considered to be a
neurodevelopmental disorder; therefore, it would be ideal to study each developmental stage.
ASD is also known as a spectrum disorder due to the heterogeneity of the symptoms. It has even
been referred to as “autisms.”
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CHAPTER 5. CONCLUSION
From previous published studies it is hypothesized that ASD has a multi-factorial
etiology that culminates to cause the disease’s behavioral phenotype. Researchers have been
sequencing the genomes of ASD patients to compare against typically developing controls in
hopes of finding a unique genetic etiology. However, these experiments have left more questions
than answers. Clues of the etiology and future treatment targets may lie in studying the pathology
of ASD. In these experiments, frozen brain regions BA24 and BA10 were used to analyze
pyramidal neuron gene expression and tissue homogenate protein concentration that may be
related to GABAergic expression. This study did not identify any significant differences between
ASD or TD for either of the experiments in either of the brain regions. While there were trends
in gene expression upregulation for two of the GABAergic receptor genes evaluated, they failed
to make statistical significance. While this study did not conclusively identify GABAergic
related pathology, it will help shape future studies for other targets of the NTRK2 pathway in
human ASD pathology.
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APPENDIX: Supplementary Information
Appendix Table 1. Thermocycler Steps cDNA and Pre-Amplification for All Genes.
Thermocycler Steps

1

2

3

4

5

cDNA

10 min,
25C

30 min,
50C

5 min,
85C

20 min,
37C

GABBR1 (DT)

2 min,
95C

30 sec,
95C

15 sec,
67C

18S rRNA (DT)

2 min,
95C

30 sec,
95C

15 sec,
53C

GABRA4 (HS)

5 min,
95C

45 sec,
94C

25 sec,
69C

Beta2Microglobulin (HS) 5 min,
95C

45 sec,
94C

2 sec,
52C

5 min,
95C

45 sec,
94C

50 sec,
65C

Hold,
1ul RNaseH
1 min, 72C
Repeat 2-4
18X
1 min, 72C
Repeat 2-4
17X
1 min, 72C
Repeat 2-4
25X
1 min, 72C
Repeat 2-4
18X
1 min, 72C
Repeat 2-4
20X

GABRA1 (HS)
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6

5 min,
72C

Hold, 4C

5 min,
72C

Hold, 4C

10 min,
72C

Hold, 4C

10 min,
72C

Hold, 4C

10 min,
72C

Hold, 4C

Appendix Table 2. Primer Sequence and Accession Number
Target or Reference Gene

Primer Sequence

GABRA1

F- TGCCCATGCTTGCCCACTAA
R- GACGTGATCCATCTTCTGCTACAACC
F- GTGCAGAGAGAGAAGCATCCTGAAG
R- TGGTTTCCCACCTCAGTTCTGTTG
F- TCACTTCGACTCTGGACGACCT
R- GGCACAGCTGGATCTGAGAAGAAA
F- GTAACCCGTTGAACCCCATT
R- CCATCCAATCGGTAGTAGCG
F- GACTTTGTCACAGCCCAAG
R- GCAAGCAAGCAGAATTTGG

GABRA4
GABBR1
18S Ribosomal RNA
Beta 2 Microglobulin
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Genebank Accession
Number
NM_001127645
NM_001204267
NM_021903
NR_003286
NM_004048

Appendix Table 3. Optimization Details for Preamplification of Primer Pairs.
Optimized
Primers

Enzyme

Temperature

Cycles

cDNA Conc.

qPCR Temp

GABRA1

HotStar

65

20

Full

57

GABBR1

DreamTaq

67

18

Half

59

GABRA4

HotStar

69

25

Full

57

18S

DreamTaq

53

17

Forth

58

Beta2M

HotStar

52

18

Forth

57
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Appendix Table 4. Master Mix Concentration Pre-Amp and qPCR
Target or Reference
Gene
GABRA1
GABRA4
GABBR1
18S Ribosomal RNA
Beta 2 Microglobulin

Pre-Amplification
H2O - 4.9 µl
Enz - 6 µl
Primer - 0.6 ul
H2O - 5.05 µl
Enz - 6 µl
Primer - 0.45 µl
H2O - 4.85 µl
Enz - 6 µl
Primer - 0.65 µl
H2O - 4.9 µl
Enz - 6 µl
Primer - 0.5 µl
H2O - 5.05 µl
Enz - 6 µl
Primer - 0.45 µl

RT-qPCR
H2O - 6.8 µl
Enz - 9 µl
Primer - 1.2 µl
H2O – 6.8 µl
Enz - 9 µl
Primer - 1.2 µl
H2O - 6.8 µl
Enz - 9 µl
Primer - 1.2 µl
H2O - 6.8 µl
Enz - 9 µl
Primer - 1.2 µl
H2O - 6.9 µl
Enz - 9 µl
Primer - 1.1 µl
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Appendix Table 5. Gene Selection and Reasoning
GABAa Receptor Subunits

Information

GABRA1

BDNF downregulates via JAK/STAT Pathway

GABRA4

BDNF upregulates via MAP Kinase Pathway

GABAb Receptor Subunits
GABBR1

Essential for GPCR function
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Appendix Table 6. Antibodies Used for Immunoblotting
Protein

Source

RRID#

Secondary Ab

Spinophilin*

Cell Signaling
cat#14136S

AB_2572261

D-a-RabbitHRP

PSD-95*

Cell Signaling cat#3450S

AB_2292883

D-a-RabbitHRP

IGF1R*

Cell Signaling cat#3027S

AB_2122378

D-a-RabbitHRP

mTOR*

Cell Signaling cat#2983S

AB_2105622

D-a-RabbitHRP

Aggrecan*

Invitrogen cat#AHP0022

AB_2536346

S-a-MouseHRP

PARP1*

Cell Signaling cat#9532S

AB_659884

D-a-RabbitHRP

CPLX1*

Abcam ab231347

AB_2861372

D-a-RabbitHRP

GapDH*

EMD Millipore
cat#MAB374

AB_2107445

S-a-MouseHRP

Sheep anti mouse IgG
HRP+

GE Healthcare UK
Limited cat#NA931V

AB_772210

Donkey anti Rabbit IgG GE Healthcare UK
HRP+
Limited cat#NA934V

AB_772206

*indicates a primary antibody
+indicates secondary antibody
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Appendix Table 7. Primary Antibody Overnight Incubation Solution
Protein

Solution

Spinophilin

6 mL 5% milk in PBS-Tween20 + 6 µL Spinophilin

PSD-95

6 mL 5% BSA in TBST + 6 µL PSD-9

IGF1R

6 mL 5% BSA in TBST + 6 µL IGF1R

mTOR

6 mL 5% BSA in TBST + 6 µL mTOR

Aggrecan

6 mL 5% BSA in TBST + 6 µL Aggrecan

PARP1

6 mL 5% milk in TBST + 6 µL PARP1

CPLX1

6 mL 5% milk in PBS-Tween20 + 6 µL CPLX1

GapDH

6 mL 5% milk in TBST + 1.2 µL GapDH
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Appendix Table 8. Buffers for Western Blotting
Buffers

Components or Source

PBS 10X

Fisher Bioreagents- cat# BP3994

TE-Lysis

Fisher Scientific- (TrisHCl- EDTA)

Lameli (Loading)*

BioRad Laboratories- 4x Lameli Sample Buffer cat#
161-0747
800mL distilled water, 30.4g Tris (Tris base), 144.2g
Glycine, 10.0g of SDS. Volumize to 1L
800mL distilled water, 30.3g Tris (Tris base), 144.1g
Glycine. Volumize to 1L
15g Glycine, 1g SDS, 10mL Tween20, pH 2.2.
Volumize to 1L

10X Running Stock**
10X Transfer Stock***
Mild Stripping Buffer
5% Milk Solution

1.25g of evaporated milk in 25 mL of PBS-Tween20

Note for T5:
*10% BME is added to the loading buffer to make 1X solution. An amount of 20 μL to 180 μL of
loading buffer.
**The running buffer used for gel electrophoresis is a dilution of the 10x stock. To prep the
running buffer, obtain 100 mL of running buffer and dilute with 900 mL of distilled water. Place
in the fridge as it needs to be cold before use.
***For the transfer buffer used in transfer step, take 100 mL from the 10X stock, add 200 mL of
methanol and then dilute with 700 mL of distilled water. Place in the fridge as it needs to be cold
before use.
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Appendix Table 9. Cycle Optimization with HotStar Enzyme
69°C, 57° C w/ HotStar

11/05/2020

GABRA4

Threshold

12

25.56

16

20.87

20

17.14

24

15.35

Punch

18.13

Blank

37.23

+ Control

30.18
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Appendix Table 10. cDNA Template Concentration Check for Threshold
69° C, 57° C w/ HotStar
3/08/2021
GABRA4

Threshold

Full

31.32

Half

31.83

Fourth

40.0

Punch

17.23

Blank

0

+ Control

28.91
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Appendix Figure 1. A) Graph of GABRA4 cycle optimization B) Graph of GABRA4 Template
concentration check for threshold
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Appendix Table 11. Cycle Optimization with HotStar Enzyme
67°C, 59° C w/ DreamTaq
1/24/2021
GABBR1

Threshold

14

25.25

18

22.58

F24

-

Punch

7.95

Blank

32.9

+ Control

20.02
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Appendix Table 12. cDNA Template Concentration Check for Threshold
67° C, 59° C w/ DreamTaq
3/17/2021
GABBR1

Threshold

Full

18.73

Half

20.33

Fourth

21.06

Punch

13.66

Blank

36.52

+ Control

24.72

69

Appendix Figure 2. A) Graph of GABBR1 cycle optimization B) Graph of GABBR1 Template
concentration check for threshold
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Appendix Figure 3. Panel A) Protein Expression of Spinophilin was determined by
immunoblotting in human postmortem tissue from frontal cortex, BA10 (N=121), punch
dissected brain tissue from TD control tissue and ASD tissue. Spinophilin protein expression was
normalized to the protein expression of GAPDH. A paired Student’s t-test was used to
determine statistical significance of p<0.05. Panel B) PSD95 (N=10), Panel
C) IGF1R (N=12), Panel D) mTOR (N=12), Panel E) CPLX1 (N=11), and Panel
F) PARP1 (N=10).
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Appendix Figure 4. Panel A) Protein Expression of Spinophilin was determined by
immunoblotting in human postmortem tissue from anterior cingulate cortex, BA24
(N=101), punch dissected brain tissue from TD control tissue and ASD
tissue. Spinophilin protein expression was normalized to the protein expression of GAPDH. A
paired Student’s t-test was used to determine statistical significance of p<0.05.
Panel B) PSD95 (N=11), Panel C) IGF1R (N=10), Panel D) mTOR (N=11), Panel
E) CPLX1 (N=11), and Panel F) PARP1 (N=10).
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